Bayer adjusted profit gains 15.8 percent on Monsanto, consumer health


© Reuters. FILE PHOTO: The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal

FRANKFURT (Reuters) – Bayer’s adjusted core earnings rose 15.8 percent in the fourth quarter, boosted by the addition of U.S. seeds maker Monsanto (NYSE:) and as its consumer healthcare business bounced back from earlier declines.

Fourth-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose to 2.07 billion euros (1.78 billion pounds), the maker of pharmaceuticals and farming pesticides said on Wednesday, beating the average analyst projection of 2.0 billion euros.

Previously announced write-downs on the value of consumer health brands and one-off charges from the closure of a German haemophilia drug plant led to a quarterly net loss of 3.9 billion euros.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

READ  Dechra ramps up contingency plan for a potential hard Brexit





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here